Monitor for COVID-19 vaccine resistance evolution during clinical trials
Open Access
- 9 November 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 18 (11) , e3001000
Abstract
Although less common than the evolution of antimicrobial drug resistance, vaccine resistance can and has evolved. How likely is it that COVID-19 vaccines currently in development will be undermined by viral evolution? We argue that this can be determined by repurposing samples that are already being collected as part of clinical trials. Such information would be useful for prioritizing investment among candidate vaccines and maximizing the potential long-term impact of COVID-19 vaccines.Keywords
This publication has 13 references indexed in Scilit:
- Comprehensive Evaluation of the Expressed CD8+ T Cell Epitope Space Using High-Throughput Epitope MappingFrontiers in Immunology, 2019
- Why the evolution of vaccine resistance is less of a concern than the evolution of drug resistanceProceedings of the National Academy of Sciences, 2018
- Why does drug resistance readily evolve but vaccine resistance does not?Proceedings Of The Royal Society B-Biological Sciences, 2017
- Imperfect Vaccination Can Enhance the Transmission of Highly Virulent PathogensPLOS Biology, 2015
- Serotype replacement in disease after pneumococcal vaccinationThe Lancet, 2011
- Insight into Evolution of Bordetella pertussis from Comparative Genomic Analysis: Evidence of Vaccine-Driven SelectionMolecular Biology and Evolution, 2010
- Glycoconjugate vaccines and immune interference: A reviewVaccine, 2010
- Optimizing Influenza Vaccine DistributionScience, 2009
- A Recombinant Blood‐Stage Malaria Vaccine ReducesPlasmodium falciparumDensity and Exerts Selective Pressure on Parasite Populations in a Phase 1–2b Trial in Papua New GuineaThe Journal of Infectious Diseases, 2002
- Vaccination against colonizing bacteria with multiple serotypesProceedings of the National Academy of Sciences, 1997